In Vivo Analysis of Wild‐type and FTDP‐17 Tau Transgenic Mice
The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
A bstract: Mutations in the coding and intronic regions of the tau gene cause frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP‐17). Some of these mutations lead to an overproduction of tau isoforms with four microtubule‐binding repeats, followed by the development of fibrillary lesions and selective cell death. In order to analyze the development of these neurofibrillary lesions in transgenic mice, the longest four‐repeat human brain tau isoform was expressed under control of two different neuron‐specific promoters. In a first model, utilizing the human Thy1 promoter, transgenic tau was hyperphosphorylated and abnormally localized to cell bodies and dendrites. In a second model, which made use of a human Thy1.2 expression vector, transgenic expression levels were much higher, and an additional phenotype was observed: Large numbers of pathologically enlarged axons containing neurofilament‐ and tau‐immunoreactive spheroids were present, especially in spinal cord. Signs of Wallerian degeneration and neurogenic muscle atrophy were observed. Behaviorally, transgenic mice showed signs of muscle weakness. Our data show that overexpression of human four‐repeat tau in itself is sufficient to lead to nerve cell dysfunction and amyotrophy. We have now extended our initial studies by introducing exonic mutations including G2 t 2V and PS01L into the tau gene in order to achieve a more advanced FTDP‐17 associated phenotype.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology
Sturchler-Pierrat, C., Abramowski, D., Duke, M., Wiederhold, K.-H., Mistl, C., Rothacher, S., Ledermann, B., Bürki, K., Frey, P., Paganetti, P. A., et al. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.24.13287 · Cited by 1,507
Self-citationLewis, J., McGowan, E., Rockwood, J., Melrose, H., Nacharaju, P., Van Slegtenhorst, M., Gwinn-Hardy, K., Murphy, M. P., Baker, M., Yu, X., et al. (2000) · Nature Genetics · doi:10.1038/78078 · Cited by 1,371
Goedert, M., & Jakes, R. (1990) · The EMBO Journal · doi:10.1002/j.1460-2075.1990.tb07870.x · Cited by 929
Self-citationTau filament formation in transgenic mice expressing P301L tau
Götz, J., Chen, F., Barmettler, R., & Nitsch, R. M. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m006531200 · Cited by 495
Self-citationTrinczek, B., Ebneth, A., Mandelkow, E.-M., & Mandelkow, E. (1999) · Journal of Cell Science · doi:10.1242/jcs.112.14.2355 · Cited by 344
Delayed embryonic lethality in mice lacking protein phosphatase 2A catalytic subunit Cα
Götz, J., Probst, A., Ehler, E., Hemmings, B., & Kues, W. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.21.12370 · Cited by 220
Self-citationEvans, D. R. H., Myles, T., Hofsteenge, J., & Hemmings, B. A. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.34.24038 · Cited by 65
Cited by
Post-translational modifications of tau protein in Alzheimer’s disease
Gong, C.-X., Liu, F., Grundke-Iqbal, I., & Iqbal, K. (2005) · Journal of Neural Transmission · doi:10.1007/s00702-004-0221-0 · Cited by 437
Synaptic changes in Alzheimer’s disease and its models
Pozueta, J., Lefort, R., & Shelanski, M. L. (2013) · Neuroscience · doi:10.1016/j.neuroscience.2012.05.050 · Cited by 307
Kimura, T., Yamashita, S., Fukuda, T., Park, J., Murayama, M., Mizoroki, T., Yoshiike, Y., Sahara, N., & Takashima, A. (2007) · The EMBO Journal · doi:10.1038/sj.emboj.7601917 · Cited by 144
“With this thought in mind, researchers have generated transgenic (Tg) mice that express human tau with the FTDP-17 mutation (Gotz et al, 2000, 2001, 2004; Lewis et al, 2000, 2001; Ishihara et al, 2001; Tanemura et al, 2001, 2002; Tatebayashi et al, 2002; Egashira et al, 2005; Lee et al, 2005;…”
BackgroundMethodJohnson, G. V. W., & Bailey, C. D. C. (2002) · Journal of Alzheimer's Disease · doi:10.3233/jad-2002-4505 · Cited by 61
Hyperphosphorylated tau is a cause of neuronal dysfunction in tauopathy
Takashima, A. (2008) · Journal of Alzheimer s Disease · doi:10.3233/jad-2008-14403 · Cited by 40
“…studying and understanding the mechanisms underlying NFT formation may lead to new strategies for preventing tauopathy-associated dementias [11,14–16, 24– 26, Although most mouse models of FTDP-17 mutant tau exhibit NFTs, neuronal loss, and behavioral deficits, one model does not: 12-month-old…”
Metadata
- Authors
- GÖTZ, J., BARMETTLER, R., FERRARI, A., GOEDERT, M., PROBST, A., & NITSCH, R. M.
- Venue
- Annals of the New York Academy of Sciences
- Publisher
- Wiley
- Published
- 2000-12
- Volume
- 920
- Issue
- 1
- Pages
- 126-133
- ISSN
- 0077-8923 (ISSN-L)
- 1749-6632
- OpenAlex
- W2048236936
- Cited by
- 26
- References
- 7
- FWCI
- 1.13
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: In Vivo Analysis of Wild‐type and FTDP‐17 Tau Transgenic Mice. https://app.cochat.ai/papers/10.1111/j.1749-6632.2000.tb06914.x
- The paper
- GÖTZ, J., BARMETTLER, R., FERRARI, A., GOEDERT, M., PROBST, A., & NITSCH, R. M. (2000). In Vivo Analysis of Wild‐type and FTDP‐17 Tau Transgenic Mice. Annals of the New York Academy of Sciences. https://doi.org/10.1111/j.1749-6632.2000.tb06914.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.